Abstract:Xue-Mei Liu, 1, 2, &ast Liu Yang, 1, 2, &ast Qi-Bin Yang 1 1 Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, 637000, People's Republic of China; 2 Department of Clinical Medicine, Graduate School of North Sichuan Medical College, Nanchong, Sichuan Province, 637000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qi-Bin Yang, Department of Rheumatology and Immunology, Affiliated Hospital, North Sichuan Medical College, 1 Maoyuannan Road, Nanchong, Sichuan Province, 637000, People's Republic of China, Tel +86-817-259-8221, Email Rheumatic disease is a disease which is not yet fully clarified to etiology and also involved in a local pathological injury or systemic disease. With the continuous improvement of clinical medical research in recent years, the development process of rheumatic diseases has been gradually elucidated; with the intensely study of epigenetics, it is realized that environmental changes can affect genetics, among which histone acetylation is one of the essential mechanisms in epigenetics. Histone deacetylases (HDACs) play an important role in regulating gene expression in various biological processes, including differentiation, development, stress response, and injury. HDACs are involved in a variety of physiological processes and are promising drug targets in various pathological conditions, such as cancer, cardiac and neurodegenerative diseases, inflammation, metabolic and immune disorders, and viral and parasitic infections. In this paper, we reviewed the roles of HDACs in rheumatic diseases in terms of their classification and function. Keywords: histone deacetylase, histone deacetylase inhibitor, rheumatic diseases Epigenetic regulation plays a vital role in gene regulation through chemical modifications of DNA and post-translational modifications of histones. Many studies in recent years have found epigenetic involvement in the pathogenesis of rheumatic immune diseases, and histone acetylation is one of the crucial mechanisms in epigenetics. 1 So far, the family of mammalian zinc-dependent histone deacetylases (HDACs) can be divided into three classes: 2 Class I (HDACs 1–3, 8), Class II (IIa: HDACs 4, 5, 7, 9; IIb: HDACs 6, 10) and Class IV (HDAC 11); and Class III, a family of sirtuin proteins, including SIRT 1–7, where the deacetylation of histones and non-histones by HDACs alters the chromatin conformation and changes the activity of transcription factors, leading to changes in gene expression. 1,3,4 HDACs have different expression sites, distribution and regulation of target genes, Immune diseases are closely related to acetylation levels, and histone deacetylase inhibitors could prevent the onset and progression of disease and be a new approach to treating rheumatic disorders. This review focused on the progress of HDACs research about immune regulation involved in rheumatic diseases to provide a basis for clinical treatment (Table 1). Table 1 Effects of HDACs in Rheumatic Diseases Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic synovitis with severe pain and swelling, joint damage and disability, ultimately leading to destruction and loss of function. 39 The current worldwide prevalence of RA is 0.5%. 40 Recently, it was suggested that epigenetic factors linking genetics and gene expression to disease risk could be a promising area. 41 Histone deacetylase 1 (HDAC1) is closely associated with the development of RA. HDAC1 interferes with the differentiation, maturation, and apoptosis of osteoclasts and promotes the development of bone destruction in RA. 42 Hawtree et al found that HDAC1 expression was significantly higher in RA synovial fibroblasts (RASFs) than in osteoarthritic (OA) synovial fibroblasts (OASFs). It was demonstrated in vitro experiments that HDAC1 knockdown inhibited the proliferation, migration, and invasion of RASFs, and inhibition of HDAC1 significantly reduced joint swelling and attenuated cartilage and joint damage in RA animal models. 5 Moreover, many T cells could be detected in the synovium of RA patients. T cells were viewed to play a central role in the pathogenesis of RA due to their ability to drive the activation of B cells, monocytes, macrophages, and fibroblast-like synoviocytes. 6 Göschl et al found a significant reduction in inflammatory cytokines interleukin (IL)-17 and IL-6 in the serum from mice with T cell-specific deletion of HDAC1, demonstrating that mice with T cell-specific deletion of HDAC1 were resistant to the development of collagen-induced arthritis (CIA). 43 -Abstract Truncated-

Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes

Histone Deacetylase 3 Facilitates TNFα-mediated NF-κB Activation Through Suppressing CTSB Induced RIP1 Degradation and is Required for Host Defense Against Bacterial Infection

HDAC2 exacerbates rheumatoid arthritis progression via the IL‐17‐CCL7 signaling pathway

Advanced Progress of Histone Deacetylases in Rheumatic Diseases

Novel mechanistic study of HDAC6 regulation of rheumatoid arthritis via CMA: exploring potential therapeutic targets

Histone Demethylase JMJD3 Regulates Fibroblast‐like Synoviocyte‐mediated Proliferation and Joint Destruction in Rheumatoid Arthritis

Extracellular CIRP induces abnormal activation of fibroblast-like synoviocytes from patients with RA via the TLR4-mediated HDAC3 pathways

HDAC3 Mediates the Inflammatory Response and LPS Tolerance in Human Monocytes and Macrophages

Hypoxia-inducible Factor-1Α and Interleukin 33 Form a Regulatory Circuit to Perpetuate the Inflammation in Rheumatoid Arthritis.

Epi-revolution in rheumatology: the potential of histone deacetylase inhibitors for targeted rheumatoid arthritis intervention

Acacetin inhibits expression of matrix metalloproteinases via a MAPK-dependent mechanism in fibroblast-like synoviocytes.

Epigenetic regulatory axis MIR22‐TET3‐MTRNR2L2 represses fibroblast‐like synoviocyte‐mediated inflammation in Rheumatoid Arthritis

Critical Role of histone deacetylase 3 in the regulation of kidney inflammation and fibrosis

Integrative function of histone deacetylase 3 in inflammation

Therapeutic Effects of NK-HDAC-1, a Novel Histone Deacetylase Inhibitor, on Collagen-Induced Arthritis Through the Induction of Apoptosis of Fibroblast-Like Synoviocytes

Gut microbial metabolite targets HDAC3-FOXK1-interferon axis in fibroblast-like synoviocytes to ameliorate rheumatoid arthritis

Notch‐1 and Notch‐3 Mediate Hypoxia‐Induced Activation of Synovial Fibroblasts in Rheumatoid Arthritis

Blockade of rheumatoid arthritis synovial fluid-induced sensory neuron activation by JAK inhibitors

KIF1C and new Huntingtin-interacting protein 1 binding proteins regulate rheumatoid arthritis fibroblast-like synoviocytes' phenotypes

HIF-1α dependent RhoA as a novel therapeutic target to regulate rheumatoid arthritis fibroblast-like synoviocytes migration in vitro and in vivo

HDAC1 regulates inflammation and osteogenic differentiation of ankylosing spondylitis fibroblasts through the Wnt-Smad signaling pathway